Flavonol aglycone with mast-cell-stabilising activity (inhibits PLA2 + histamine release), nlrp3 inflammasome inflammasome suppression, and zinc-ionophore activity (shuttles Zn²⁺ across cell membranes, repurposed in early COVID protocols). CD38 inhibitor — preserves cellular nad plus (see niacin nad synthesis) by slowing its CD38-driven hydrolysis. Poorly bioavailable as aglycone; glucoside forms (rutin, isoquercitrin) have better absorption.
Half-Life & Elimination Curve (PO: 11h)
Plasma (PO)t½ Decay (11h)
0×t½0h100%(0.101 mg/L)
1×t½11h50%(50.5 µg/L)
2×t½22h25%(25.2 µg/L)
3×t½33h12.5%(12.6 µg/L)
4×t½44h6.3%(6.31 µg/L)
5×t½55h3.1%(3.16 µg/L)
Elimination t½11h (PO)
Rate Constant (ke)0.063 h⁻¹
Time to Peak (Tmax)4.74h
Est. Peak (Cmax)0.101 mg/L
Clearance (CL)6.18 L/h
97% Washout (5×t½)55h
Dosing Guidelines
Oral (PO): Typical 667 mg (Range: 500–1000 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 2% · Volume of Distribution (Vd): 98 L · Absorption (ka): 0.5 h⁻¹ (t½ka ≈ 1.39h) [PMID 11361045]
Zinc (synergistic): Ionophore mechanism — intracellular Zn²⁺ rises with co-administration.
Piperine (synergistic): Piperine increases quercetin F; standard bioavailability-enhancer pairing.
Fisetin (synergistic): Both flavonols with overlapping senolytic and CD38-inhibitory activity.
Rutin (synergistic): Rutin is the rhamnoglucoside prodrug of quercetin. Quercetin aglycone has higher and faster plasma exposure; rutin is slower-release via microbial deglycosylation.